CN103038211B - 3-苯氧基甲基吡咯烷化合物的结晶形式 - Google Patents

3-苯氧基甲基吡咯烷化合物的结晶形式 Download PDF

Info

Publication number
CN103038211B
CN103038211B CN201180033815.4A CN201180033815A CN103038211B CN 103038211 B CN103038211 B CN 103038211B CN 201180033815 A CN201180033815 A CN 201180033815A CN 103038211 B CN103038211 B CN 103038211B
Authority
CN
China
Prior art keywords
crystalline salt
crystalline
pain
salt according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180033815.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103038211A (zh
Inventor
大介·罗兰·齐藤
米罗斯拉夫·拉普塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Shiwan Pharmaceutical
Theravance Biopharma R&D IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44510052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103038211(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shiwan Pharmaceutical, Theravance Biopharma R&D IP LLC filed Critical Shiwan Pharmaceutical
Publication of CN103038211A publication Critical patent/CN103038211A/zh
Application granted granted Critical
Publication of CN103038211B publication Critical patent/CN103038211B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180033815.4A 2010-07-09 2011-06-30 3-苯氧基甲基吡咯烷化合物的结晶形式 Expired - Fee Related CN103038211B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36277310P 2010-07-09 2010-07-09
US61/362,773 2010-07-09
PCT/US2011/042518 WO2012006205A1 (en) 2010-07-09 2011-06-30 Crystalline form of a 3-phenoxymethylpyrrolidine compound

Publications (2)

Publication Number Publication Date
CN103038211A CN103038211A (zh) 2013-04-10
CN103038211B true CN103038211B (zh) 2015-04-15

Family

ID=44510052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180033815.4A Expired - Fee Related CN103038211B (zh) 2010-07-09 2011-06-30 3-苯氧基甲基吡咯烷化合物的结晶形式

Country Status (20)

Country Link
US (4) US8163794B2 (enExample)
EP (1) EP2590941A1 (enExample)
JP (2) JP5823512B2 (enExample)
KR (1) KR20130041916A (enExample)
CN (1) CN103038211B (enExample)
AR (1) AR083512A1 (enExample)
AU (1) AU2011276416B2 (enExample)
BR (1) BR112013000602A2 (enExample)
CA (1) CA2803090A1 (enExample)
CL (1) CL2013000085A1 (enExample)
CO (1) CO6680604A2 (enExample)
IL (1) IL223584A0 (enExample)
MX (1) MX2013000334A (enExample)
NZ (1) NZ605490A (enExample)
PH (1) PH12013500051A1 (enExample)
RU (1) RU2013105479A (enExample)
SG (1) SG186789A1 (enExample)
TW (1) TW201206882A (enExample)
WO (1) WO2012006205A1 (enExample)
ZA (1) ZA201300154B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2535669C2 (ru) * 2009-07-13 2014-12-20 Тереванс, Инк. 3-феноксиметилпирролидиновые соединения
NZ605490A (en) * 2010-07-09 2014-10-31 Theravance Biopharma R & D Ip Llc Crystalline form of a 3-phenoxymethylpyrrolidine compound
US12369722B2 (en) 2018-05-23 2025-07-29 L&P Property Management Company Method of disassembling pocketed spring assembly with dimensionally stabilizing substrate
US11013340B2 (en) 2018-05-23 2021-05-25 L&P Property Management Company Pocketed spring assembly having dimensionally stabilizing substrate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506164A (zh) * 2006-08-23 2009-08-12 辉瑞产品公司 哌啶衍生物
TW201008912A (en) * 2008-07-24 2010-03-01 Theravance Inc 3-(phenoxyphenylmethyl)pyrrolidine compounds
CN102471258A (zh) * 2009-07-13 2012-05-23 施万制药 3-苯氧基甲基吡咯烷化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
DE60119047D1 (de) * 2000-08-31 2006-06-01 Pfizer Phenoxyphenylheterozyklen als Serotonin-Wiederaufnahmehemmer
EP1725518A1 (en) * 2004-03-05 2006-11-29 Eli Lilly And Company Pharmaceutical compounds
US20100292288A1 (en) * 2007-06-08 2010-11-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
NZ605490A (en) * 2010-07-09 2014-10-31 Theravance Biopharma R & D Ip Llc Crystalline form of a 3-phenoxymethylpyrrolidine compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506164A (zh) * 2006-08-23 2009-08-12 辉瑞产品公司 哌啶衍生物
TW201008912A (en) * 2008-07-24 2010-03-01 Theravance Inc 3-(phenoxyphenylmethyl)pyrrolidine compounds
CN102471258A (zh) * 2009-07-13 2012-05-23 施万制药 3-苯氧基甲基吡咯烷化合物

Also Published As

Publication number Publication date
IL223584A0 (en) 2013-03-05
US8791151B2 (en) 2014-07-29
CN103038211A (zh) 2013-04-10
JP5823512B2 (ja) 2015-11-25
AU2011276416B2 (en) 2015-04-02
US20150080450A1 (en) 2015-03-19
KR20130041916A (ko) 2013-04-25
WO2012006205A1 (en) 2012-01-12
CL2013000085A1 (es) 2013-03-15
BR112013000602A2 (pt) 2016-07-05
US20120010265A1 (en) 2012-01-12
EP2590941A1 (en) 2013-05-15
US9120746B2 (en) 2015-09-01
US20120178790A1 (en) 2012-07-12
US20140018407A1 (en) 2014-01-16
PH12013500051A1 (en) 2017-10-25
JP2015120752A (ja) 2015-07-02
CO6680604A2 (es) 2013-05-31
MX2013000334A (es) 2013-02-26
US8163794B2 (en) 2012-04-24
AU2011276416A1 (en) 2013-02-14
SG186789A1 (en) 2013-02-28
NZ605490A (en) 2014-10-31
US8383669B2 (en) 2013-02-26
ZA201300154B (en) 2013-09-25
CA2803090A1 (en) 2012-01-12
RU2013105479A (ru) 2014-08-20
AR083512A1 (es) 2013-03-06
TW201206882A (en) 2012-02-16
JP2013532170A (ja) 2013-08-15

Similar Documents

Publication Publication Date Title
US12239638B2 (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
TWI438190B (zh) ３－（苯氧基苯基甲基）吡咯啶化合物
CN103038211B (zh) 3-苯氧基甲基吡咯烷化合物的结晶形式
HK1160449B (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SCHWAN BIOPHARMA RESEARCH + DEVELOPMENT IP CO., LT

Free format text: FORMER OWNER: SCHWAN PHARMACY

Effective date: 20140901

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140901

Address after: California, USA

Applicant after: THERAVANCE BIOPHARMA R&D IP, LLC

Address before: California, USA

Applicant before: Shi Wanzhiyao

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150415

CF01 Termination of patent right due to non-payment of annual fee